Author:
Huang Xing,Zhang Chang-Hao,Deng Hao,Wu Dan,Guo Hong-Yan,Lee Jung Joon,Chen Fen-Er,Shen Qing-Kun,Jin Li-Li,Quan Zhe-Shan
Abstract
A series of quillaic acid derivatives with different substituents on the 28-carboxyl group were designed and synthesized. Five human cancer cell lines (HCT116, BEL7402, HepG2, SW620, and MCF-7) were evaluated for their antitumor activity in vitro. Some of the tested derivatives showed improved antiproliferative activity compared to the lead compound, quillaic acid. Among them, compound E (IC50 = 2.46 ± 0.44 μM) showed the strongest antiproliferative activity against HCT116 cells; compared with quillaic acid (IC50 > 10 μM), its efficacy against HCT116 cancer cells was approximately 4-fold higher than that of quillaic acid. Compound E also induces cell cycle arrest and apoptosis by modulating NF-κB and MAPK pathways. Therefore, the development of compound E is certainly valuable for anti-tumor applications.
Reference51 articles.
1. 1, 3, 4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents;Bajaj;Eur. J. Med. Chem.,2015
2. Design, synthesis and biological assessment of 1, 3, 4-oxadiazole incorporated oxazole-triazine derivatives as anticancer agents;Balaraju;Chem. Data Collect.,2021
3. Structurally modified glycyrrhetinic acid derivatives as anti-inflammatory agents;Bian;Bioorg. Chem.,2021
4. 1, 2, 3-triazoles as peptide bond isosteres: Synthesis and biological evaluation of cyclotetrapeptide mimics;Bock;Org. Biomol. Chem.,2007
5. Chemical composition and biological activities of propolis samples from different geographical regions of Turkey;Boke Sarikahya;Phytochem. Lett.,2021